BANK VONTOBEL/CALL/MODERNA/135/0.1/20.09.24 | Market Closed - Euronext Paris 10:00:01 17/05/2024 pm IST | ||
| 1.51 EUR | +2.03% |
|
| Current month | +80.25% | ||
| 1 month | +137.40% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 1.46 | -1.35% |
| 16/24/16 | 1.48 | +19.35% |
| 15/24/15 | 1.24 | -8.15% |
| 14/24/14 | 1.35 | +28.57% |
| 13/24/13 | 1.05 | +23.53% |
Real-time Euronext Paris
Last update May 17, 2024 at 10:00 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| PQ46V | |
| ISIN | DE000VM7WHG9 |
| Date issued | 04/01/2024 |
| Strike | 135 $ |
| Maturity | 20/09/2024 (125 Days) |
| Parity | 10 : 1 |
| Emission price | 1.44 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.61 € |
|---|---|
| Lowest since issue | 0.36 € |
| Spread | 0.02 € |
| Spread % | 1.32% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
132.9
USD
Average target price
138.5
USD
Spread / Average Target
+4.22%
- Stock Market
- Warrants
- PQ46V Warrant
